Augmented Lipocalin-2 Is Associated with Chronic Obstructive Pulmonary Disease and Counteracts Lung Adenocarcinoma Development
Warapen Treekitkarnmongkol(The University of Texas MD Anderson Cancer Center), Humam Kadara(The University of Texas MD Anderson Cancer Center), Carmen Behrens, Shanshan Deng(University of Tennessee Health Science Center), Avrum Spira(Boston University), Joshua K. Ochieng(Erasmus MC - Sophia Children’s Hospital), Smruthy Sivakumar(The University of Texas MD Anderson Cancer Center), Seyed Javad Moghaddam(The University of Texas MD Anderson Cancer Center), Ignacio I. Wistuba(The University of Texas MD Anderson Cancer Center), Tina L. McDowell, Ansam Sinjab, Zahraa Rahal(American University of Beirut), Junya Fukuoka(Nagasaki University Hospital), Edwin R. Parra(The University of Texas MD Anderson Cancer Center), Xu Li(The University of Queensland), Florencia McAllister(The University of Texas MD Anderson Cancer Center), Paul Scheet(The University of Texas MD Anderson Cancer Center), Sayuri Nunomura‐Nakamura(University of Nagasaki), Edwin J. Ostrin(General Department of Preventive Medicine), Jiexin Zhang(Southern Medical University), Tina Cascone(The University of Texas MD Anderson Cancer Center), Kyle Chang(Baylor College of Medicine), Maria Gabriela Raso, Kieko Hara, Junya Fujimoto(The University of Texas MD Anderson Cancer Center), Alexandre Reuben(The University of Texas MD Anderson Cancer Center), Maya Hassane, Jianling Zhou, Luisa M. Solis(The University of Texas MD Anderson Cancer Center), Jacob Kantrowitz(Boston University), Wenhua Lang, Wei Lü(The University of Texas MD Anderson Cancer Center)
Cited by 46
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
|Cell|2018|2k
Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine
|Science|2017|1.8k
Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in <i>NOTCH1</i>
|Science|2011|1.7k
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
|Nature Reviews Clinical Oncology|2021|1.5k